Tumour-Infiltrating FoxP3+ and IL-17-Producing T Cells Affect the Progression and Prognosis of Gallbladder Carcinoma after Surgery

Scandinavian Journal of Immunology

Volumn 78, Issue 6, 2013, Pages 516-522

  Zhang, Y ^a   Huang, Y ^a   Qin, M ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN NANKAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; BILIARY TRACT SURGERY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DISTANT METASTASIS; FEMALE; GALLBLADDER CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; T LYMPHOCYTE;

AGED; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GALLBLADDER NEOPLASMS; HUMANS; INTERLEUKIN-17; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; NEOPLASM METASTASIS; SURVIVAL;

EID: 84888414446     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12109     Document Type: Article

References (39)

1. Yang XW, Yang J, Li L et al. Analysis of the relationships between clinicopathologic factors and survival in gallbladder cancer following surgical resection with curative intent. PLoS ONE 2012;7:e51513.
2. Balachandran P, Agarwal S, Krishnani N et al. Predictors of long-term survival in patients with gallbladder cancer. J Gastrointest Surg 2006;10:848-54.
3. Park JS, Yoon DS, Kim KS et al. Analysis of prognostic factors after curative resection for gallbladder carcinoma. Korean J Gastroenterol 2006;48:32-6.
4. Bettelli E, Carrier Y, Gao W et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006 May 11;441:235-8.
5. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009;27:485-517.
6. Dong C. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol 2006;6:329-33.
7. Sakaguchi S, Ono M, Setoguchi R et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006;212:8-27.
8. Feuerer M, Hill JA, Mathis D, Benoist C. Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol 2009;10:689-95.
9. Huang M, Wang FM, Wang T et al. Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients. Digestion 2012;86:329-37.
10. Wang F, Jing X, Li G et al. Foxp3+ regulatory T cells are associated with the natural history of chronic hepatitis B and poor prognosis of hepatocellular carcinoma. Liver Int 2012;32:644-55.
11. Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006;12:5423-34.
12. Sellitto A, Galizia G, De Fanis U et al. Behavior of circulating CD4+CD25+Foxp3+ regulatory T cells in colon cancer patients undergoing surgery. J Clin Immunol 2011;31:1095-104.
13. Zhang Y, Ma D, Tian Y, Wang X, Qiao Y, Cui B. The imbalance of Th17/Treg in patients with uterine cervical cancer. Clin Chim Acta 2011;412:894-900.
14. Tokuno K, Hazama S, Yoshino S, Yoshida S, Oka M. Increased prevalence of regulatory T-cells in the peripheral blood of patients with gastrointestinal cancer. Anticancer Res 2009;29:1527-32.
15. Clarke SL, Betts GJ, Plant A et al. CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE 2006;1:e129.
16. Hong H, Gu Y, Zhang H et al. Depletion of CD4 + CD25 + reg-ulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model. Clin Exp Immunol 2010;159:93-9.
17. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008;28:454-67.
18. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007;8:345-50.
19. Zhang JP, Yan J, Xu J et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009;50:980-9.
20. Chen X, Wan J, Liu J et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 2010;69:348-54.
21. Sfanos KS, Bruno TC, Maris CH et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 2008;14:3254-61.
22. Zhang B, Rong G, Wei H et al. The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 2008;374:533-7.
23. Chen D, Hu Q, Mao C et al. Increased IL-17-producing CD4(+) T cells in patients with esophageal cancer. Cell Immunol 2012;272:166-74.
24. Wang J, Cai D, Ma B, Wu G, Wu J. Skewing the balance of regulatory T-cells and T-helper 17 cells in breast cancer patients. J Int Med Res 2011;39:691-701.
25. Maruyama T, Kono K, Mizukami Y et al. Distribution of Th17 cells and FoxP3(+)regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci 2010;101:1947-54.
26. Gao Q, Qiu SJ, Fan J et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007;25:2586-93.
27. Hou F, Li Z, Ma D et al. Distribution of Th17 cells and Foxp3-expressing T cells in tumor-infiltrating lymphocytes in patients with uterine cervical cancer. Clin Chim Acta 2012;413:1848-54.
28. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3 + reg-ulatory T cells in the human immune system. Nat Rev Immunol 2010;10:490-500.
29. Salama P, Phillips M, Grieu F et al. Tumor-infiltrating FOXP3 + T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009;27:186-92.
30. Yoshioka T, Miyamoto M, Cho Y et al. Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinoma. Br J Cancer 2008;98:1258-63.
31. Kryczek I, Wu K, Zhao E et al. IL-17 + regulatory T cells in the microenvironments of chronic inflammation and cancer. J Immunol 2011;186:4388-95.
32. Peng LS, Zhuang Y, Shi Y et al. Increased tumor-infiltrating CD8(+)Foxp3(+) T lymphocytes are associated with tumor progression in human gastric cancer. Cancer Immunol Immunother 2012;61:2183-92.
33. deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 2012;18:3022-9.
34. Kryczek I, Banerjee M, Cheng P et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009;114:1141-9.
35. Lv L, Pan K, Li XD et al. The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS ONE 2011;6:e18219.
36. Chen JG, Xia JC, Liang XT et al. Intratumoral expression of IL-17 and its prognostic role in gastric adenocarcinoma patients. Int J Biol Sci 2011;7:53-60.
37. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009;206:1457-64.
38. Liu J, Duan Y, Cheng X et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 2011;407:348-54.
39. Gaur P, Qadir GA, Upadhyay S, Singh AK, Shukla NK, Das SN. Skewed immunological balance between Th17 (CD4(+)IL17A (+)) and Treg (CD4 (+)CD25 (+)FOXP3 (+)) cells in human oral squamous cell carcinoma. Cell Oncol (Dordr) 2012;35:335-43.